Literature DB >> 10423035

The gene for multiple endocrine neoplasia type 1: recent findings.

S J Marx1, S K Agarwal, C Heppner, Y S Kim, M B Kester, P K Goldsmith, M C Skarulis, A M Spiegel, A L Burns, L V Debelenko, Z Zhuang, I A Lubensky, L A Liotta, M R Emmert-Buck, S C Guru, P Manickam, J S Crabtree, F S Collins, S C Chandrasekharappa.   

Abstract

Multiple endocrine neoplasia type 1 (MENI) is a promising model to understand endocrine and other tumors. Its most common endocrine expressions are tumors of parathyroids, entero-pancreatic neuro-endocrine tissue, and anterior pituitary. Recently, collagenomas and multiple angiofibromas of the dermis also have been recognized as very common. MEN1 can be characterized from different perspectives: (a) as a hormone (parathyroid hormone, gastrin, prolactin, etc.) excess syndrome with excellent therapeutic options; (b) as a syndrome with sometimes lethal outcomes from malignancy of entero-pancreatic neuro-endocrine or foregut carcinoid tissues; or (c) as a disorder than can give insight about cell regulation in the endocrine, the dermal, and perhaps other tissue systems. The MEN1 gene was identified recently by positional cloning, a comprehensive strategy of narrowing the candidate interval and evaluating all or most genes in that interval. This discovery has opened new approaches to basic and clinical issues. Germline MEN1 mutations have been identified in most MEN1 families. Germline MENI mutations were generally not found in families with isolated hyperparathyroidism or with isolated pituitary tumor. Thus, studies with the MENI gene helped establish that mutation of other gene(s) is likely causative of these two MEN1 phenocopies. MEN1 proved to be the gene most frequent L4 mutated in common-variety, nonhereditary parathyroid tumor, gastrinoma, insulinoma, or bronchial carcinoid. For example, in common-variety parathyroid tumors, mutation of several other genes (such as cyclin D1 and P53) has been found, but much less frequently than MEN1 mutation. The majority of germline and somatic MEN1 mutations predicted truncation of the encoded protein (menin). Such inactivating mutations strongly supported prior predictions that MEN1 is a tumor suppressor gene insofar as stepwise mutational inactivation of both copies can release a cell from normal growth suppression. Menin is principally a nuclear protein; menin interacts with junD. Future studies, such as discovery of menin's metabolic pathway, could lead to new opportunities in cell biology and in tumor therapy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10423035     DOI: 10.1016/s8756-3282(99)00112-x

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  5 in total

Review 1.  In search of tumor suppressing functions of menin.

Authors:  Yuqing Yang; Xianxin Hua
Journal:  Mol Cell Endocrinol       Date:  2007-01-11       Impact factor: 4.102

Review 2.  Isolation and characterization of novel pituitary tumor related genes: a cDNA representational difference approach.

Authors:  Xun Zhang; Yunli Zhou; Anne Klibanski
Journal:  Mol Cell Endocrinol       Date:  2010-03-06       Impact factor: 4.102

3.  Rapid mutation scanning of genes associated with familial cancer syndromes using denaturing high-performance liquid chromatography.

Authors:  D J Marsh; G Theodosopoulos; V Howell; A L Richardson; D E Benn; A L Proos; C Eng; B G Robinson
Journal:  Neoplasia       Date:  2001 May-Jun       Impact factor: 5.715

4.  Diffuse large B-cell lymphoma in the thyroid gland associated with primary hyperparathyroidism.

Authors:  Toshihisa Ogawa; Hajime Kanauchi; Makoto Kammori; Yoshikazu Mimura; Satoshi Ota; Michio Kaminishi
Journal:  Int J Clin Oncol       Date:  2007-02-25       Impact factor: 3.402

5.  High-resolution metabolic phenotyping of genetically and environmentally diverse potato tuber systems. Identification of phenocopies.

Authors:  U Roessner; L Willmitzer; A R Fernie
Journal:  Plant Physiol       Date:  2001-11       Impact factor: 8.340

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.